RVMD - Revolution Medicines, Inc.
IEX Last Trade
44.105
0.145 0.329%
Share volume: 31,912
Last Updated: Fri 27 Dec 2024 08:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$43.96
0.15
0.33%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-07 | 2023-02-27 | 2023-05-08 | 2023-08-08 | 2023-11-06 | 2024-02-26 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 632.802 M | 825.910 M | 811.930 M | 1.073 B | 1.074 B | 984.232 M | 2.062 B | 1.908 B | |
| Current Assets | 483.046 M | 675.108 M | 660.185 M | 922.753 M | 922.092 M | 824.467 M | 1.879 B | 1.729 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 15.989 M | 15.155 M | 10.569 M | 8.958 M | 10.093 M | 10.963 M | 25.072 M | 25.662 M | |
| Short Term Investments | 15.989 M | 15.155 M | 10.569 M | 8.958 M | 10.093 M | 10.963 M | 25.072 M | 25.662 M | |
| Total Receivables | 5.624 M | 4.940 M | 4.673 M | 3.995 M | 2.510 M | 309.000 K | 1.254 M | 0.000 | |
| Current Cash | 461.433 M | 655.013 M | 644.943 M | 909.800 M | 909.489 M | 813.195 M | 1.853 B | 1.704 B | |
| Total Non-current Assets | 149.756 M | 150.802 M | 151.745 M | 150.495 M | 151.617 M | 159.765 M | 182.424 M | 179.160 M | |
| Property Plant Equipment | 15.910 M | 18.267 M | 18.659 M | 18.536 M | 19.718 M | 20.286 M | 22.865 M | 23.697 M | |
| Other Assets | 58.159 M | 57.115 M | 57.934 M | 57.074 M | 56.424 M | 64.474 M | 84.181 M | 80.352 M | |
| Intangible Assets | 59.342 M | 59.075 M | 58.807 M | 58.540 M | 58.273 M | 58.006 M | 57.739 M | 57.472 M | |
| Goodwill | 14.608 M | 14.608 M | 14.608 M | 14.608 M | 14.608 M | 14.608 M | 14.608 M | 14.608 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 632.802 M | 825.910 M | 811.930 M | 1.073 B | 1.074 B | 984.232 M | 2.062 B | 1.908 B | |
| Total liabilities | 133.961 M | 144.491 M | 126.742 M | 121.030 M | 142.874 M | 146.774 M | 235.511 M | 182.895 M | |
| Total current liabilities | 63.539 M | 73.271 M | 61.984 M | 54.635 M | 78.059 M | 85.541 M | 143.851 M | 93.723 M | |
| Accounts Payable | 14.067 M | 24.382 M | 21.306 M | 19.912 M | 29.784 M | 29.627 M | 61.788 M | 32.379 M | |
| Other liabilities | 4.056 M | 5.889 M | 301.000 K | 1.694 M | 252.000 K | 982.000 K | 7.970 M | 6.197 M | |
| Current long term debt | 6.030 M | 7.017 M | 6.773 M | 5.921 M | 5.718 M | 5.755 M | 7.369 M | 8.169 M | |
| Long term debt | 58.922 M | 58.183 M | 57.432 M | 57.676 M | 57.538 M | 57.093 M | 80.575 M | 79.860 M | |
| Other liabilities | 4.056 M | 5.889 M | 301.000 K | 1.694 M | 252.000 K | 982.000 K | 7.970 M | 6.197 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 498.841 M | 681.419 M | 685.188 M | 952.218 M | 930.835 M | 837.458 M | 1.826 B | 1.725 B | |
| Common stock | 74.281 M | 84.695 M | 89.368 M | 94.832 M | 106.884 M | 109.233 M | 141.650 M | 164.729 M | |
| Retained earnings | -571.505 M | -644.834 M | -701.341 M | -769.439 M | -867.737 M | -976.171 M | -1.138 B | -1.254 B |